Protocol Ledger

NCT04527107 · Phase II · COMPLETED

A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema

Interventional Phase II clinical trial protocol NCT04527107 sponsored by Oxurion in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-07-31 Enrollment: 135 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04527107
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)135 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04527107
Protocol FieldVerified Registry Value
NCT IdentifierNCT04527107
Consolidated Lead SponsorOxurion
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment135 participants (ACTUAL)
Registered Start Date2020-07-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04527107
Hospital Research SiteLocationSite Profile
Retina Vitreous Associates Medical GroupBeverly Hills, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI